Trials / Completed
CompletedNCT02179346
Observational Study With NOVOCART® Inject in the Reconstruction of the Hip Joint With Full Thickness Cartilage Defects
Observational Study on the Feasibility, Safety and Efficacy in the Biological Reconstruction of the Hip Joint With Full Thickness Cartilage Defects With an in Situ Polymerizable and Chondrocyte Populated Biomaterial (NOVOCART® Inject)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 21 (actual)
- Sponsor
- Tetec AG · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Non-interventional study to evaluate safety and efficacy of NOVOCART® Inject in patients with full thickness cartilage defects in the hip.
Detailed description
Prospective and multicenter non-interventional study to evaluate safety and efficacy of NOVOCART® Inject in patients with impingement syndrom in the hip. Safety: 24-month post treatment follow up period by measuring the number of adverse drug reactions/serious adverse drug reactions. Efficacy: 24-month post treatment follow up period using iHOT 33 and EuroQuol-5D-5L.
Conditions
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2018-06-01
- Completion
- 2018-06-18
- First posted
- 2014-07-01
- Last updated
- 2019-12-06
Locations
3 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT02179346. Inclusion in this directory is not an endorsement.